The TGFβ (transforming growth factor β) superfamily proteins are pleiotropic cytokines that regulate a diverse range of cellular processes, including proliferation, differentiation, migration, adhesion and death.  The TGFβ superfamily elicits 4 signaling pathways: TGFβ, Bone Morphogenic Protein (BMP), Activin, and Nodal.  Each pathway signals through a heteromeric receptor complex composed of at least two type-I and two type-II transmembrane receptors containing cytoplasmic serine/threonine kinase domains. These receptors are distinguished by the presence of a glycine/serine-rich juxta-membrane domain found only in the type I receptors. Either type receptor may initially bind ligand, followed by the recruitment of an alternate-type receptor counterpart to form a signal-activating complex. TGFBR3 (TGFβ receptor 3), also known as BGCAN and Betaglycan, is a transmembrane proteoglycan with a large extracellular domain and a short cytoplasmic domain that lacks an obvious signaling motif. TGFR3 functions as a co-receptor with other TGFBR superfamily members.  It may be involved in capturing and retaining the ligand for presentation to the signaling receptors. TGFBR3 binds TGFβ2 with the highest affinity and other TGFβ isoforms with lower affinities. Cellular responsiveness to TGFβ2 is dependent on the presence of TGFBR3. Ectodomain shedding produces a soluble form of TGFBR3, which binds TGFβ and exhibits antagonistic activity. Reduced expression of TGFBR3 has been observed in various cancers. Genetic variations in TGFBR3 are associated with Vogt-Koyanagi-Harada (VKH) disease and Behcet's disease (BD).

The TGFβ (transforming growth factor β) superfamily proteins are pleiotropic cytokines that regulate a diverse range of cellular processes, including proliferation, differentiation, migration, adhesion and death.  The TGFβ superfamily elicits 4 signaling pathways: TGFβ, Bone Morphogenic Protein (BMP), Activin, and Nodal.  Each pathway signals through a heteromeric receptor complex composed of at least two type-I and two type-II transmembrane receptors containing cytoplasmic serine/threonine kinase domains. These receptors are distinguished by the presence of a glycine/serine-rich juxta-membrane domain found only in the type I receptors. Either type receptor may initially bind ligand, followed by the recruitment of an alternate-type receptor counterpart to form a signal-activating complex. TGFBR3 (TGFβ receptor 3), also known as BGCAN and Betaglycan, is a transmembrane proteoglycan with a large extracellular domain and a short cytoplasmic domain that lacks an obvious signaling motif. TGFR3 functions as a co-receptor with other TGFBR superfamily members.  It may be involved in capturing and retaining the ligand for presentation to the signaling receptors. TGFBR3 binds TGFβ2 with the highest affinity and other TGFβ isoforms with lower affinities. Cellular responsiveness to TGFβ2 is dependent on the presence of TGFBR3. Ectodomain shedding produces a soluble form of TGFBR3, which binds TGFβ and exhibits antagonistic activity. Reduced expression of TGFBR3 has been observed in various cancers. Genetic variations in TGFBR3 are associated with Vogt-Koyanagi-Harada (VKH) disease and Behcet's disease (BD).

 

Product Details

 

Gene Symbol: TGFBR3; TGFBRIII; TGFBR-3; TGFR-3; TGFR-III; BGCAN; betaglycan

 

NCBI Gene ID: 7049

 

Uniprot Entry: Q03167

 

Construct Details: Full length human TGFBR3/BGCAN gene is subcloned into the Lentiviral expression vector pLTC with an upstream CMV promoter, which can be used for both transient and stable expression in mammalian cells.  It can be co-transfected with the LentiPAK DNA mix (SKU# LP-001) into HEK293 cells to produce high titer lentiviral particles.

 

Vector Type: pLTC (lentiviral expression vector containing a heterologous CMV promoter, see the vector map above)

 

Gene Insert Sequence:  

ATGACTTCCCATTATGTGATTGCCATCTTTGCCCTGATGAGCTCCTGTTTAGCCACTGCAGGTCCAGAGCCTGGTGCACT

GTGTGAACTGTCACCTGTCAGTGCCTCCCATCCTGTCCAGGCCTTGATGGAGAGCTTCACTGTTTTGTCAGGCTGTGCCA

GCAGAGGCACAACTGGGCTGCCACAGGAGGTGCATGTCCTGAATCTCCGCACTGCAGGCCAGGGGCCTGGCCAGCTACAG

AGAGAGGTCACACTTCACCTGAATCCCATCTCCTCAGTCCACATCCACCACAAGTCTGTTGTGTTCCTGCTCAACTCCCC

ACACCCCCTGGTGTGGCATCTGAAGACAGAGAGACTTGCCACTGGGGTCTCCAGACTGTTTTTGGTGTCTGAGGGTTCTG

TGGTCCAGTTTTCATCAGCAAACTTCTCCTTGACAGCAGAAACAGAAGAAAGGAACTTCCCCCATGGAAATGAACATCTG

TTAAATTGGGCCCGAAAAGAGTATGGAGCAGTTACTTCATTCACCGAACTCAAGATAGCAAGAAACATTTATATTAAAGT

GGGGGAAGATCAAGTGTTCCCTCCAAAGTGCAACATAGGGAAGAATTTTCTCTCACTCAATTACCTTGCTGAGTACCTTC

AACCCAAAGCAGCAGAAGGGTGTGTGATGTCCAGCCAGCCCCAGAATGAGGAAGTACACATCATCGAGCTAATCACCCCC

AACTCTAACCCCTACAGTGCTTTCCAGGTGGATATAACAATTGATATAAGACCTTCTCAAGAGGATCTTGAAGTGGTCAA

AAATCTCATCCTGATCTTGAAGTGCAAAAAGTCTGTCAACTGGGTGATCAAATCTTTTGATGTTAAGGGAAGCCTGAAAA

TTATTGCTCCTAACAGTATTGGCTTTGGAAAAGAGAGTGAAAGATCTATGACAATGACCAAATCAATAAGAGATGACATT

CCTTCAACCCAAGGGAATCTGGTGAAGTGGGCTTTGGACAATGGCTATAGTCCAATAACTTCATACACAATGGCTCCTGT

GGCTAATAGATTTCATCTTCGGCTTGAAAATAATGCAGAGGAGATGGGAGATGAGGAAGTCCACACTATTCCTCCTGAGC

TACGGATCCTGCTGGACCCTGGTGCCCTGCCTGCCCTGCAGAACCCGCCCATCCGGGGAGGGGAAGGCCAAAATGGAGGC

CTTCCGTTTCCTTTCCCAGATATTTCCAGGAGAGTCTGGAATGAAGAGGGAGAAGATGGGCTCCCTCGGCCAAAGGACCC

TGTCATTCCCAGCATACAACTGTTTCCTGGTCTCAGAGAGCCAGAAGAGGTGCAAGGGAGCGTGGATATTGCCCTGTCTG

TCAAATGTGACAATGAGAAGATGATCGTGGCTGTAGAAAAAGATTCTTTTCAGGCCAGTGGCTACTCGGGGATGGACGTC

ACCCTGTTGGATCCTACCTGCAAGGCCAAGATGAATGGCACACACTTTGTTTTGGAGTCTCCTCTGAATGGCTGCGGTAC

TCGGCCCCGGTGGTCAGCCCTTGATGGTGTGGTCTACTATAACTCCATTGTGATACAGGTTCCAGCCCTTGGGGACAGTA

GTGGTTGGCCAGATGGTTATGAAGATCTGGAGTCAGGTGATAATGGATTTCCGGGAGATATGGATGAAGGAGATGCTTCC

CTGTTCACCCGACCTGAAATCGTGGTGTTTAATTGCAGCCTTCAGCAGGTGAGGAACCCCAGCAGCTTCCAGGAACAGCC

CCACGGAAACATCACCTTCAACATGGAGCTATACAACACTGACCTCTTTTTGGTGCCCTCCCAGGGCGTCTTCTCTGTGC

CAGAGAATGGACACGTTTATGTTGAGGTATCTGTTACTAAGGCTGAACAAGAACTGGGATTTGCCATCCAAACGTGCTTT

ATCTCTCCATATTCGAACCCTGATAGGATGTCTCATTACACCATTATTGAGAATATTTGTCCTAAAGATGAATCTGTGAA

ATTCTACAGTCCCAAGAGAGTGCACTTTCCTATCCCGCAAGCTGACATGGATAAGAAGCGATTCAGCTTTGTCTTCAAGC

CTGTCTTCAACACCTCACTGCTCTTTCTACAGTGTGAGCTGACGCTGTGTACGAAGATGGAGAAGCACCCCCAGAAGTTG

CCTAAGTGTGTGCCTCCTGACGAAGCCTGCACCTCGCTGGACGCCTCGATAATCTGGGCCATGATGCAGAATAAGAAGAC

GTTCACTAAGCCCCTTGCTGTGATCCACCATGAAGCAGAATCTAAAGAAAAAGGTCCAAGCATGAAGGAACCAAATCCAA

TTTCTCCACCAATTTTCCATGGTCTGGACACCCTAACCGTGATGGGCATTGCGTTTGCAGCCTTTGTGATCGGAGCACTC

CTGACGGGGGCCTTGTGGTACATCTATTCTCACACAGGGGAGACAGCAGGAAGGCAGCAAGTCCCCACCTCCCCGCCAGC

CTCGGAAAACAGCAGTGCTGCCCACAGCATCGGCAGCACGCAGAGCACGCCTTGCTCCAGCAGCAGCACGGCCTAG

 

Formulation: Lentivector encoded and pre-packaged viral particles (typical titer 10⁶ - 10⁷ IFU/ml) in the conditional medium (serum-free) from HEK293 cells that have been transfected with the lentivector gene clone and the LentiPAK DNA mix

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Important Safety Information: With the safety features in place, our lentiviral vectors and viral particles can be employed in standard Biosafety Level 2 tissue culture facilities and should be treated with the same level of caution as any other potentially infectious agent. Any investigator who purchases our lentiviral/retroviral products & services is responsible for following Biosafety Level 2 requirements on the handling of viral particles. For more information on Biosafety Level 2 agents and practices, please refer to NIH’s “Biosafety Considerations for Research with Lentiviral Vectors”.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C for immediate use.  Upon receipt, centrifuge the vial briefly before opening.  Store at –80°C or lower and the product is stable for 3 months.  Avoid repeated freeze-thaw cycles.

 

 

The product should be employed in a Biosafety Level 2 tissue culture facility.

 

 

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

1. Biochem. Biophys. Res. Commun. 189:356 (1992).

2. J. Hum. Genet. 45:250 (2000).

3. EMBO J. 20 (3): 480-90 (2001).

4. Oncol. Rep. 30:1301-8 (2013).

5. Curr. Eye Res. 37:312 (2012).

 

 

Documentation

 

Product datasheet (pdf) can be downloaded here: LTV0284-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.